Investigation of the predictive roles of erythropoietin, ghrelin and biochemical parameters in patients with renal failure
Archives of Advances in Biosciences,
Vol. 16 No. 1 (2025),
2 March 2025
,
Page 1-8
https://doi.org/10.22037/aab.v16i1.50536
Abstract
Introduction: kidney dysfunction is the loss of elimination of wastes of the kidneys in an adequate manner, which causes the accumulation of nitrogenous substances in the circulation. This condition is present in acute and chronic forms. The last stage renal disease (ESRD) is the terminus stage which requires renal replacement measures.
The purpose of the research was to examine how the erythropoietin and ghrelin hormones are expected to play and how the biochemical parameters play in clinical assessment of patients with renal failure.
Materials and Methods: The present study was undertaken using the sample of patients with renal failure undergoing dialysis at Baquba Teaching Hospital during the months of January to April 2022. The 62 and 35 were the patients who reported kidney failure and non-renal healthy controls, respectively. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) on serum samples were measured using the Cobas e411 analyzer. Nephric functional parameters (urea, uric acid and creatinine) were also measured on serum samples through the Cobas e411 analyzer. Ghrelin and erythropoietin hormone assays were done through the enzyme linked immunosorbent assay. The SPSS comprehension software was used to conduct the statistical analysis and data processing.
Results: Metabolic, hepatic and renal biomarkers, and hormonal values were also important (P < 0.05) between the patient group and the control group. The patients had high glucose, triglycerides, cholesterol, liver enzymes (ALT, AST and ALP) and kidney (urea, urate acid, creatinine and potassium) indicators. The patients experienced the reduction of albumin and erythropoietin. There was no significant difference between the total protein, sodium and calcium levels according to the group (p > 0.05.(
Conclusions: We found that physiological parameters are connected with the presence of renal dysfunction to a large extent. The chronic renal failure affects to a considerable extent the biochemical indicators and blood regulators, that is, the level of erythropoietin and ghrelin. The results indicate a lack of electrolyte, metabolism, and hormone homeostasis, which implies that ghrelin and erythropoietin are the possible diagnostic and treatment etiological variables in the treatment of renal diseases.
- renal failure
- erythropoietin,
- ghrelin,
- biochemical parameters
How to Cite
References
[1] Matsushita K, Ballew SH, Wang AY, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18(11):696-707. [DOI: 10.1038/s41581-022-00616-6] [PMID]
[2] Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-47. [DOI: 10.1001/jama.298.17.2038] [PMID]
[3] Martinusen D, Marin JG, Cheng E, Lau W. Chronic kidney disease and end stage renal disease. In: Braund R, editor. Renal medicine and clinical pharmacy. Cham: Springer; 2020. p. 45-115. [DOI: 10.1007/978-3-030-37655-0_4]
[4] Peters F, Westphal C, Kramer A, Westerman R. Is the rise in the prevalence of renal replacement therapy at older ages the price for living longer? Front Public Health. 2018;6:138. [DOI: 10.3389/fpubh.2018.00138] [PMID]
[5] Rosique-Esteban N, Guasch-Ferré M, Hernández-Alonso P, Salas-Salvadó J. Dietary magnesium and cardiovascular disease: a review with emphasis in epidemiological studies. Nutrients. 2018;10(2):168. [DOI: 10.3390/nu10020168] [PMID]
[6] Al-Hetty HRAK, Rajab WJ, Al-Kubaisi FMA, Ali AY. Evaluation of serum magnesium in obesity and overweight and normal weight. Egypt J Chem. 2022;65(SI:13B):255-62. [DOI: 10.21608/ejchem.2022.119956.5384]
[7] Reznikov KM, Gorbunova NS, Kolesnichenko PD, Tverskoy AV, Kostina DA, Bashkatova DA, Nikitina VA. Search of new pharmaceuticals on the basis of darbepoetin in the treatment of ischemic stroke (review of literature). Research Result: Pharmacology and Clinical Pharmacology. 2017;3(1):125-36. [DOI: 10.18413/2500-235X-2017-3-1-125-136]
[8] Suresh S, Rajvanshi PK, Noguchi CT. The many facets of erythropoietin physiologic and metabolic response. Front Physiol. 2020;10:1534. [DOI: 10.3389/fphys.2019.01534] [PMID]
[9] Zhang Y, Zhu X, Huang X, Wei X, Zhao D, Jiang L, Zhao X, Du Y. Advances in understanding the effects of erythropoietin on renal fibrosis. Front Med (Lausanne). 2020;7:47. [DOI: 10.3389/fmed.2020.00047] [PMID]
[10] Boniecka I, Jeznach-Steinhagen A, Michalska W, Rymarz A, Szostak-Węgierek D, Niemczyk S. Nutritional status, selected nutrients intake and their relationship with the concentration of ghrelin and adiponectin in patients with diabetic nephropathy. Nutrients. 2021;13(12):4416. [DOI: 10.3390/nu13124416] [PMID]
[11] Mahmood IS, Sarhat ER. Effects of chronic renal failure and hemodialysis on serum levels of apelin and ghrelin. Biochem Cell Arch. 2022;22(1):2097-103. [LINK]
[12] Rashad NM, Sami MM, Al-Sayed RM, Kamal NM. Association of plasma and mRNA expression levels of ghrelin with nutritional status in Egyptian patients with end-stage renal disease on regular hemodialysis. Egypt J Hosp Med. 2022;88(1):3878-84. [DOI: 10.21608/EJHM.2022.252232]
[13] Vaziri ND. Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clin Exp Nephrol. 2014;18(2):265-8. [DOI: 10.1007/s10157-013-0847-z] [PMID]
[14] Bulbul MC, Dagel T, Afsar B, Ulusu NN, Kuwabara M, Covic A, Kanbay M. Disorders of lipid metabolism in chronic kidney disease. Blood Purif. 2018;46(2):144-52. [DOI: 10.1159/000488816] [PMID]
[15] Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G, Gesualdo L, De Nicola L; Italian Diabetes Society and the Italian Society of Nephrology. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. Nutr Metab Cardiovasc Dis. 2019;29(11):1127-50. [DOI: 10.1016/j.numecd.2019.07.017] [PMID]
[16] Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61(10):2098-107. [DOI: 10.1007/s00125-018-4669-0] [PMID]
[17] Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis. 2013;33(4):380-8. [DOI: 10.1055/s-0033-1358519] [PMID]
[18] Zhang J, Zhang R, Wang Y, Li H, Han Q, Wu Y, Wang T, Liu F. The level of serum albumin is associated with renal prognosis in patients with diabetic nephropathy. J Diabetes Res. 2019;2019:7825804. [DOI: 10.1155/2019/7825804] [PMID]
[19] Gatta A, Verardo A, Bolognesi M. Hypoalbuminemia. Intern Emerg Med. 2012;7 Suppl 3:S193-9. [DOI: 10.1007/s11739-012-0802-0] [PMID]
[20] Iwasaki T, Togashi Y, Terauchi Y. Significant association of serum albumin with severity of retinopathy and neuropathy, in addition to that of nephropathy, in Japanese type 2 diabetic patients. Endocr J. 2008;55(2):311-6. [DOI: 10.1507/endocrj.K07-086] [PMID]
[21] Sette LH, de Almeida Lopes EP. Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a comprehensive review. Clinics (Sao Paulo). 2014;69(4):271-8. [DOI: 10.6061/clinics/2014(04)09] [PMID]
[22] Zong L, Wang X, Li Z, Zhao X, Liu L, Li H, Meng X, Wang Y, Wang Y. Alkaline phosphatase and outcomes in patients with preserved renal function: results from China National Stroke Registry. Stroke. 2018;49(5):1176-82. [DOI: 10.1161/STROKEAHA.118.020237] [PMID]
[23] Drechsler C, Verduijn M, Pilz S, Krediet RT, Dekker FW, Wanner C, Ketteler M, Boeschoten EW, Brandenburg V; NECOSAD Study Group. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol. 2011;6(7):1752-9. [DOI: 10.2215/CJN.10091110] [PMID]
[24] Chen C, Yang L, Li H, Chen F, Chen C, Gao R, Lv XY, Tang J. Raman spectroscopy combined with multiple algorithms for analysis and rapid screening of chronic renal failure. Photodiagnosis Photodyn Ther. 2020;30:101792. [DOI: 10.1016/j.pdpdt.2020.101792] [PMID]
[25] Ficheux A, Gayrard N, Szwarc I, Soullier S, Bismuth-Mondolfo J, Brunet P, Servel MF, Argilés A. Use of spent dialysate analysis to estimate blood levels of uraemic solutes without blood sampling: urea. Nephrol Dial Transplant. 2010;25(3):873-9. [DOI: 10.1093/ndt/gfp539] [PMID]
[26] Dhondup T, Qian Q. Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure. Blood Purif. 2017;43(1-3):179-88. [DOI: 10.1159/000452725] [PMID]
[27] He J, Mills KT, Appel LJ, Yang W, Chen J, Lee BT, Rosas SE, Porter A, Makos G, Weir MR, Hamm LL; Chronic Renal Insufficiency Cohort Study Investigators. Urinary sodium and potassium excretion and CKD progression. J Am Soc Nephrol. 2016;27(4):1202-12. [DOI: 10.1681/ASN.2015010022] [PMID]
[28] Panjeta M, Tahirović I, Sofić E, Ćorić J, Dervišević A. Interpretation of erythropoietin and haemoglobin levels in patients with various stages of chronic kidney disease. J Med Biochem. 2017;36(2):145-52. [DOI: 10.1515/jomb-2017-0014] [PMID]
[29] Farsijani NM, Liu Q, Kobayashi H, Davidoff O, Sha F, Fandrey J, Ikizler TA, O’Connor PM, Haase VH. Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin. J Clin Invest. 2016;126(4):1425-37. [DOI: 10.1172/JCI74997] [PMID]
[30] Souma T, Yamazaki S, Moriguchi T, Suzuki N, Hirano I, Pan X, Minegishi N, Abe M, Kiyomoto H, Ito S, Yamamoto M. Plasticity of renal erythropoietin-producing cells governs fibrosis. J Am Soc Nephrol. 2013;24(10):1599-616. [DOI: 10.1681/ASN.2013010030] [PMID]
[31] Kobayashi H, Terao T, Tsushima T, Abe Y, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue K. Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma. Cancer Med. 2020;9(12):4460-6. [DOI: 10.1002/cam4.3050] [PMID]
[32] Fujita Y, Doi Y, Hamano T, Hatazaki M, Umayahara Y, Isaka Y, Tsubakihara Y. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study. Sci Rep. 2019;9(1):14871. [DOI: 10.1038/s41598-019-51207-8] [PMID]
[33] Bunn RC, Cockrell GE, Ou Y, Thrailkill KM, Lumpkin CK Jr, Fowlkes JL. Palmitate and insulin synergistically induce IL-6 expression in human monocytes. Cardiovasc Diabetol. 2010;9:73. [DOI: 10.1186/1475-2840-9-73] [PMID]
[34] Park SY, Lee JY, Tak WY, Kweon YO, Lee MS. Erythropoietin decreases carbon tetrachloride-induced hepatic fibrosis by inhibiting transforming growth factor-beta. Chin Med J (Engl). 2012;125(17):3098-103. [DOI: 10.3760/cma.j.issn.0366-6999.2012.17.024] [PMID]
[35] Tögel FE, Ahlstrom JD, Yang Y, Hu Z, Zhang P, Westenfelder C. Carbamylated erythropoietin outperforms erythropoietin in the treatment of AKI-on-CKD and other AKI models. J Am Soc Nephrol. 2016;27(11):3394-404. [DOI: 10.1681/ASN.2015091059] [PMID]
[36] Canpolat N, Sever L, Agbas A, Tasdemir M, Oruc C, Ekmekci OB, Caliskan S. Leptin and ghrelin in chronic kidney disease: their associations with protein-energy wasting. Pediatr Nephrol. 2018;33(11):2113-22. [DOI: 10.1007/s00467-018-4002-7] [PMID]
[37] Boshra V, Abbas AM. Effects of peripherally and centrally applied ghrelin on the oxidative stress induced by renin angiotensin system in a rat model of renovascular hypertension. J Basic Clin Physiol Pharmacol. 2017;28(4):347-54. [DOI: 10.1515/jbcpp-2016-0145] [PMID]
[38] Sun GX, Ding R, Li M, Guo Y, Fan LP, Yue LS, Li LY, Zhao M. Ghrelin attenuates renal fibrosis and inflammation of obstructive nephropathy. J Urol. 2015;193(6):2107-15. [DOI: 10.1016/j.juro.2014.11.098] [PMID]
- Abstract Viewed: 154 times
- PDF Downloaded: 12 times